Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 981 results for "for merck"

Merck inaugurates its new biomass plant in India
Bio Spectrum Asia

Merck inaugurates its new biomass plant in India

Singapore: German drug giant Merck has, today, commissioned a climate-neutral co-generation plant at its production site in Goa, India. The initiative is a part of Merck's company-wide climate protection program. Earlier this year, the drug maker ... Bio Spectrum Asia, 53 minutes ago
Merck's biomass power plant commissioned in India Energy Business Review, 48 minutes ago

315 images for for merck

Bio Spectrum Asia, 51 minutes ago
MedIndia, 1 day ago
Industry Week, 1 day ago
Jutia Group, 23 hours ago
McDuffieMirror, 2 days ago
EFE, 1 day ago
Hawaii News Now, 3 days ago
Philly.com, 2 days ago
West Australian, 2 days ago
Corante, 1 day ago
CBC

Daily Dividend Report: MRK, CBS, ADI, BDC, FGP

Merck (NYSE:MRK) has increased the company's quarterly dividend to $0.45 per outstanding share of the company's common stock, up $0.01 from $0.44 per outstanding share paid last quarter. Payment will be made on Jan. 8, 2015, to stockholders of ...
 Market News Video19 hours ago Merck Hikes Quarterly Dividend  RTTNews.com1 day ago Merck declares $0.45 dividend  Seeking Alpha1 day ago Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine  PharmTech.com1 day ago
[x]  

Watch for Shares of Merck (MRK) to Approach Resistance at $59.91

Merck (NYSE:MRK) has opened bullishly above the pivot of $59.38 today and has reached the first level of resistance at $59.62. Investors may be interested in a cross of the next upside pivot targets of $59.91
 Individual.com19 hours ago Merck (MRK) Crosses Pivot Point Resistance at $59.62  Individual.com20 hours ago Merck (MRK) Crosses Pivot Point Support at $59.27  Comtex SmarTrend6 days ago

Merck (MRK) Showing Support Near $58.85

The patented options-trade picking algorithms used by MarketIntelligenceCenter.com found a trading opportunity with Merck & Co Inc. (http://www.marketintelligencecenter.com/symbol/MRK"MRK) that should provide a 2.15% return in just 142 days. Sell ...
 Individual.com20 hours ago Potential Merck (MRK) Trade Has 5.05% Downside Protection  Individual.com2 days ago Merck (MRK) Showing Bullish Technicals With Support At $58.98  Individual.com2 days ago Potential Merck (MRK) Trade Targets 2.35% Return  Individual.com5 days ago
BusinessWeek

Company News: Calorie Count Rules, Merck, NewLink Genetics, Zalando, Gap, Barnes & Noble, Redbox

• Chain restaurants, movie theaters, and gas stations will soon be required to post calorie counts on prepared foods and beverages to comply with new rules from the U.S. Food and Drug Administration. Public health groups lauded the requirements, ...
 BusinessWeek17 hours ago

Why A Merck Clinical Trial May Help Amgen And Regeneron Shares To Set Higher Highs

Summary Last week, a major potential headwind turned into a tailwind for potential "PCSK9 inhibitor" blockbusters from Amgen and Regeneron/Sanofi. The good news was that Merck's IMPROVE-IT cholesterol study supported the "LDL hypothesis" upon ...
 Seeking Alpha22 hours ago

Merck & Co. Director Rochelle B. Lazarus Sells 10,000 Shares (MRK)

Merck & Co. (NYSE:MRK) Director Rochelle B. Lazarus unloaded 10,000 shares of Merck & Co. stock on the open market in a transaction dated Wednesday, November 26th. The stock was sold at an average price of $59.63, for a total transaction of ...
 Ticker Report15 hours ago Merck & Co. Director Unloads $295,650 in Stock (MRK)  Ticker Report1 day ago Will Merck (MRK) Stock Be Helped Today by Zetia Study?  TheStreet.com1 week ago

Merck's acute coronary syndrome study meets primary and secondary endpoints

Merck & Co., Inc. has announced that the investigational IMPROVE-IT study for VYTORIN, in patients with acute coronary syndrome, met its primary and secondary composite efficacy endpoints. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering ...
 Individual.com1 day ago IMPROVE-IT Gives Another Merck Drug Promise  Forbes.com5 days ago Merck's Vytorin Achieves Primary, Secondary Endpoints in IMPROVE-IT Study  American Journal of Managed Care1 week ago Merck & Co. says IMPROVE-IT study of Vytorin hits main goal  FirstWord Pharma1 week ago
Metro Canada

Merck Enters Ebola Vaccine Race

Merck (NYSE:MRK) is the latest among the big pharmaceutical firms to join Ebola Vaccine race. The company has just announced a deal with NewLink Genetics under which Merck will get the rights to the latter's experimental vaccine for Ebola virus and ...
 Trefis1 day ago Merck deal gives makers of made-in-Canada Ebola vaccine some big-league help  Globe and Mail2 days ago NewLink, Merck enter deal on Ebola vaccine  Metro Canada2 days ago Made-in-Canada Ebola vaccine getting help from Merck  CTV News2 days ago
[x]  
Bidness Etc

Merck announces positive data from Phase II melanoma analysis

Merck & Co., Inc. has announced that a pre-specified analysis of investigational data from a pivotal Phase II study, or KEYNOTE-002, showed KEYTRUDA, its anti-PD-1 therapy, substantially improved the primary endpoint of progression-free survival, or ...
 Individual.com3 days ago Merck Updates on Anti-PD-1 Drug Keytruda Phase II Study  Yahoo! Finance1 week ago Merck PD-1 inhibitor extends PFS in melanoma  Seeking Alpha1 week ago Anti-PD-1 Drug Keytruda Gives Merck and Co. (MRK) Reason To Rejoice Again  Bidness Etc1 week ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less